2,3:4,5-di-O-isopropylidene-L-arabinitol | 127305-49-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3:4,5-di-O-isopropylidene-L-arabinitol
• 英文别名: 1,2:3,4-di-O-isopropylidenexylitol；D-O¹,O²;O³,O⁴-diisopropylidene-xylitol；D-O¹,O²;O³,O⁴-Diisopropyliden-xylit；1,2;3,4-Di-O-isopropyliden-xylit；2,3:4,5-DI-O-Isopropylidene-D-arabitol；[(4R,5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-1,3-dioxolan-4-yl]methanol
• CAS: 127305-49-1
• 化学式: C₁₁H₂₀O₅
• 分子量: 232.277
• InChiKey: FBIWGPWXTDOFQR-VGMNWLOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3:4,5-di-O-isopropylidene-L-arabinitol 在 sodium hydride 、 C.I.酸性橙108 、 过氧化苯甲酰 作用下， 以 乙醇 为溶剂， 反应 42.33h， 生成 (Z)-5-O-<3'-(F-hexyl)-2'-propenyl>-1,2:3,4-di-O-isopropylidenexylitol
  参考文献：
  名称：

  Synthesis of perfluoroalkylated xylitol ethers and esters: new surfactants for biomedical uses

  摘要：

  New, well-defined surfactants and cosurfactants were synthesized with the objective of enhancing the stability of fluorocarbon emulsions destined to serve as oxygen carriers for biomedical applications. Monoperfluoroalkylated ethers of xylitol were achieved by addition of perfluoroalkyl iodide on the double bond of a protected xylitol allyl ether in a one-step addition-elimination reaction. Monoesters were obtained specifically on position 5 by treating 1,2:3,4-di-O-isopropylidenexylitol with perfluoroalkylated acid chlorides of various chain lengths in pyridine at room temperature. The products display strong surface activity and produce a remarkable synergistic stabilization of a fluorocarbon/Pluronic F-68 type emulsion. Biocompatibility data are reported, which include in vitro toxicity tests on Namalva cell cultures and hemolysis tests on human blood cells; the latter was found to decrease as the length of the F-alkyl chain increased. IV injection in mice (n = 10) showed that these products were innocuous at 400-1000 mg/kg of body weight. Preliminary exchange-perfusion experiments on rats with an emulsion containing the F-octyl xylitol ether were encouraging.

  DOI：

  10.1021/jm00166a028
• 作为产物：
  描述：

  Xylitol 在 zinc(II) chloride 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 24.25h， 生成 2,3:4,5-di-O-isopropylidene-L-arabinitol
  参考文献：
  名称：

  Ophthamological drugs

  摘要：

  本发明一般涉及眼科药物。更具体地，本发明涉及一种修改（衍生化）眼科药物的方法，以增加它们通过角膜的渗透性。本发明还涉及根据本方法修改（衍生化）的药物，以及将其用于治疗与眼内压升高相关的疾病，特别是青光眼。

  公开号：

  US20060135609A1

文献信息

• Reflection colour changes in cholesteric liquid crystals after the addition and photochemical isomerization of mesogenic azobenzenes tethered to sugar alcohols
  作者：Haruhisa Akiyama、Asuka Tanaka、Hideo Hiramatsu、Jun'ichi Nagasawa、Nobuyuki Tamaoki

  DOI：10.1039/b900890j

  日期：——

  We controlled reflection colour of the glass-forming cholesteric liquid crystals over the whole visible region using the smectic liquid crystalline photochromic dopants on the basis of the different mechanism from the conventional helical twisting power change, which gave rise to full-colour recording and display materials at a lower additive concentration than that reported previously. We simply tethered multiple mesogenic azobenzene units to sugar alcohols to obtain effective dopants in which the intramolecular mesogenic moieties could adopt smectic-like alignments. The new dopants that featured linear sugar alcohol backbones exhibited increasingly stable smectic phases upon increasing the number of mesogenic groups in the molecule; a corresponding cyclic sugar alcohol derivative exhibited no such smectic phase. Addition of these smectic liquid crystalline dopants to the glass-forming cholesteric liquid crystalline material induced increasingly larger pitch shifts upon increasing the number of intramolecular mesogenic groups in the dopant. Dopants prepared from stereoisomeric sugar alcohol backbones provided similar liquid crystalline phases and induced similar pitch shifts after their addition to the cholesteric liquid crystals. The colour images recorded on the thin layer of the cholesteric liquid crystalline mixture were stabilized by fixing the cholesteric alignment into glassy states, which withstood heating at 70 °C.

  我们通过基于与传统螺旋扭曲力变化不同的机制，使用层状液晶光致变色掺杂剂，控制玻璃形成胆甾相液晶在整个可见光区域的反射颜色，从而在比先前报道的更低的掺杂浓度下实现了全彩色记录和显示材料。我们简单地将多个偶氮苯介晶单元连接到糖醇上，得到了有效的掺杂剂，其中分子内介晶单元可以采取类似于层状的排列。这种新型掺杂剂具有线性糖醇骨架，随着分子中介晶基团数量的增加，展现出越来越稳定的层状相；而相应的环状糖醇衍生物则不显示层状相。将这些层状液晶掺杂剂添加到玻璃形成胆甾相液晶材料中，随着掺杂剂分子内介晶基团数量的增加，诱导了越来越大的螺距变化。从立体异构糖醇骨架制备的掺杂剂提供了相似的液晶相，并且在添加到胆甾相液晶后诱导了相似的螺距变化。记录在胆甾相液晶薄层上的彩色图像通过将胆甾相排列固定成玻璃态而稳定，能够承受70°C的加热。
• [EN] ESTER PRODRUGS OF GAMMA-LACTAMS AND THEIR USE<br/>[FR] PROMÉDICAMENTS À ESTER, COMPRENANT DES GAMMA-LACTAMES ET LEUR UTILISATION
  申请人：ALLERGAN INC

  公开号：WO2016054596A1

  公开（公告）日：2016-04-07

  Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof,and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.

  本文介绍了公式（I）的γ-内酰胺化合物的酯前药物或其药学上可接受的盐，并且介绍了这些化合物用于治疗眼部疾病，包括青光眼和黄斑变性等方法。
• REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES
  申请人：ALLERGAN, INC.

  公开号：US20140057975A1

  公开（公告）日：2014-02-27

  Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.

  本发明提供了治疗青光眼的组合物和方法。具体提供了亲水性酯前药及其用于减少中央角膜增厚的使用方法。
• OPHTHAMOLOGICAL DRUGS
  申请人：Toone Eric J.

  公开号：US20090318542A1

  公开（公告）日：2009-12-24

  The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.

  本发明通常涉及眼科药物。更具体地说，本发明涉及一种改性（衍生化）眼科药物的方法，以增加它们穿过角膜的渗透性。本发明还涉及按照本方法改性（衍生化）的药物，以及将其用于治疗与眼内压升高有关的疾病，特别是青光眼。
• ANTITUMOR AGENT
  申请人：Sugiura Reiko

  公开号：US20140121175A1

  公开（公告）日：2014-05-01

  The invention is intended to provide an excellent antitumor agent. An antitumor agent contains a glycolipid glycoside compound represented by Formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: in the formula, R 1 to R 4 are the same as or different from each other and represent an alkanoyl group or a hydrogen atom, and A represents a sugar alcohol residue or a polyol residue.

  该发明旨在提供一种优秀的抗肿瘤剂。一种抗肿瘤剂包含以式（1）表示的糖脂糖苷化合物或其药理学上可接受的盐作为活性成分：在该式中，R1到R4相同或不同，表示烷酰基或氢原子，A表示糖醇残基或多元醇残基。